<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388153</url>
  </required_header>
  <id_info>
    <org_study_id>15624</org_study_id>
    <secondary_id>2011-000904-17</secondary_id>
    <nct_id>NCT01388153</nct_id>
  </id_info>
  <brief_title>A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet</brief_title>
  <official_title>Randomized, Non-blinded, 3-fold Crossover Study to Investigate the Bioequivalence Between Glucobay ODT Taken Without and With Water and the Glucobay Standard Tablet Following Single Oral Dosing in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the bioequivalence between Glucobay ODT (Orally Disintegrating Tablet) taken
      without or with water and the Glucobay standard tablet taken with water
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of postprandial maximum concentration (Cmax) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2)</measure>
    <time_frame>within 4 hours after sucrose load</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2)</measure>
    <time_frame>within 4 hours after sucrose load</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum drug concentration in plasma after single dose (tmax) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2)</measure>
    <time_frame>within 4 hours after sucrose load</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of postprandial Cmax of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2)</measure>
    <time_frame>within 4 hours after sucrose load</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of postprandial AUC(0-4) of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2)</measure>
    <time_frame>within 4 hours after sucrose load</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2)</measure>
    <time_frame>within 4 hours after sucrose load</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose (Glucobay ODT, BAYG5421)</intervention_name>
    <description>Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose (Glucobay ODT, BAYG5421)</intervention_name>
    <description>Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose (Glucobay, BAYG5421)</intervention_name>
    <description>Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The informed consent must be signed before any study specific tests or procedures are
             done

          -  Healthy male subject

          -  Age: 18 to 45 years (inclusive) at the first screening examination / visit

          -  Ethnicity: White

          -  Body mass index (BMI): above/equal 18 and below/equal 28 kg / m²

          -  Confirmation of the subject's health insurance coverage prior to the first screening
             examination / visit

          -  Ability to understand and follow study-related instructions

        Exclusion Criteria:

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination and effects of the study drugs will
             not be normal

          -  Subjects with a medical disorder, condition or history of such that would impair the
             subject's ability to participate or complete this study in the opinion of the
             investigator or the sponsor

          -  Known hypersensitivity to the study drugs (active substances or excipients of the
             preparations)

          -  Known severe allergies, non-allergic drug reactions, or multiple drug allergies

          -  Chronic intestinal disorders associated with distinct disturbances of digestion and
             absorption

          -  States which may deteriorate as a result of increased gas formation in the intestine
             (e.g. Roemheld´s syndrome, major hernias, intestinal obstructions, intestinal ulcers,
             Crohn´s disease, ulcerative colitis, malabsorptions)

          -  Fasting blood glucose level outside normal range

          -  Impaired glucose tolerance in glucose tolerance test
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mönchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2011</study_first_submitted>
  <study_first_submitted_qc>July 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <name_title>Head Clinical Pharmacology</name_title>
    <organization>Bayer Healthcare AG</organization>
  </responsible_party>
  <keyword>Bioequivalence, acarbose, ODT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

